Morocco’s pharmaceutical sovereignty: IFMIP and industrial skills
IFMIP highlights the role of industrial skills in Morocco’s pharmaceutical sovereignty, linking training and sustainable funding to the expansion of local production.
Morocco now manufactures nearly 70% of the medicines it consumes and has Africa’s second-largest pharmaceutical industry by turnover. Yet consolidating this achievement and replacing imports with local production depend on a resource that remains in short supply: an industrial workforce trained to international standards. The Institute for Training in Pharmaceutical Industry Professions (IFMIP), designed to develop these skills, is not yet operational and remains in the development phase. This policy brief argues that pharmaceutical sovereignty will depend less on stated ambition than on aligning three timetables—construction, sustainable funding and training—and ensuring that training, regulation and industrial policy work together.
The national strategy rests on three pillars: local production, regulation and workforce training. The first two attract most public attention; the third is the least visible and potentially the most restrictive. This brief examines the causes of the remaining dependence, assesses IFMIP against its constraints, and sets out five policy directions.
Strategic context
Morocco’s pharmaceutical industry provides an established economic base: a market estimated at around MAD 35 billion, a sector employing nearly 10,000 people and local production meeting 70–80% of national needs, with exports of approximately MAD 2.2 billion. This maturity reflects a long trajectory: after independence, the country imported more than 85% of its requirements, while local coverage rose from 15% in 1960 to 70% today. The challenge is therefore not to establish an industry, but to secure its value chain and strengthen its resilience to global supply pressures, whose severity the COVID-19 pandemic exposed.
This is a substantial base: the country has a network of licensed industrial pharmaceutical establishments and exports a significant share of its production, while the sector preserved all its jobs during the health crisis. Beyond its economic contribution, the industry is becoming an instrument of national health security and regional influence as Morocco positions itself as a continental pharmaceutical hub. This ambition has implications for skills: producing for export demands more exacting quality standards than supplying the domestic market alone, and therefore more specialised technical staff.
The national pharmaceutical policy, launched in 2022, places import substitution at the heart of health sovereignty. The sector’s programme agreement aims to increase direct turnover by nearly MAD 15 billion and create around 16,000 jobs, including 5,000 direct jobs, by 2027. Meeting these targets requires an industrial economics approach: additional production facilities and technological upgrading in demanding areas—biotechnology, injectables and complex formulations. Yet each step up the value chain shifts the constraint from equipment to human capital, making training a limiting factor in the sovereignty strategy.
Case analysis: IFMIP and the sovereignty value chain
The initiative stems from a framework agreement signed on 16 April 2021 between the Department of Vocational Training, the Ministry of Industry and Trade, the General Confederation of Moroccan Enterprises, and the Moroccan Federation of Pharmaceutical Industry and Innovation. The institute is located in Nouaceur, south of Casablanca, on a site of around 56,250 m², with a construction budget of approximately MAD 99 million and capacity designed for some 510 trainees, with up to 500 a year. Developed through a competency-based approach following a 2023 capacity assessment, its training offer comprises nine programmes covering core occupations: packaging-line operation, manufacturing-process operation, line supervision and medical sales representation. It combines initial and continuing training and is designed to evolve with the sector’s needs.
The analysis must give equal weight to the opportunity and the constraint. The opportunity is that IFMIP addresses a documented gap in the training system and aligns its curricula with the industry’s actual needs. The constraint is that a production site’s value depends on the skills of the teams operating it, and its licensing is itself conditional on those skills; the institute, however, is not yet operating. There is also a question of scale: an establishment training around 500 people a year, even with scope for expansion, must be considered against a sector aiming to create several thousand jobs. IFMIP is therefore better understood as a foundation for disseminating frameworks, certifications and standards than as a single quantitative answer.
Policy pillars and recommendations
Turning ambition into effective capacity requires coordinated action across five levers.
1. Align the skills timetable with the industrial timetable.
Training a specialised technician takes longer than building a factory. The project’s sequencing—an agreement in 2021, a study in 2023, followed by a legal support phase running from April 2026 to May 2028—requires management that prevents the building’s completion from preceding the actual start of training by too long.
2. Secure the model’s financial autonomy.
The institute operates under delegated management based on a state balancing subsidy supplemented by own-source revenue whose ability to generate sufficient income is not guaranteed. A multi-year funding path is needed to prevent recurring operating costs from undermining the model after the initial investment.
3. Ensure sound training design and compliance with standards.
Qualifications that meet international standards are essential both for access to export markets and for securing domestic supply. A competency-based approach requires up-to-date technical training facilities and continuous revision of competency frameworks with industry.
4. Coordinate training, regulation and industrial policy.
The failure of the previous 2016–2020 performance agreement was attributed in part to a lack of coordination between the health and industry ministries and excessive issuance of import authorisations. Institutional coherence is at least as important to success as the quality of the training system itself.
5. Plan for wider impact.
Given its capacity, the institute should be conceived as a model that can be replicated, rather than the sole answer to a national need. Its value will lie as much in its influence on the wider training system as in its own trainee numbers.
Public–private ecosystem dynamics
The arrangement reflects a structured division of responsibilities rather than an isolated initiative: the state provides the regulatory foundation and investment, professional federations contribute occupational expertise, and funders supply technical assistance and financing. The initiative draws on a loan agreement with the French Development Agency and technical support from Expertise France, within a model of a public establishment managed by industry professionals. This shared governance is both the model’s promise—responsiveness and alignment with needs—and its main source of risk, since it requires sustained coordination among actors working to different timetables. It should be assessed as an ecosystem dynamic, not a guarantee of results.
Institutional challenges and conclusion
IFMIP completes the pharmaceutical sovereignty value chain: production requires regulation, and regulation requires training. The concept is consistent with national pharmaceutical policy and addresses a documented need. The decisive test, however, is neither signing the agreement nor completing the building. It is opening the institute on time, funding its operations sustainably, delivering training at sufficient scale and to the necessary standards, and maintaining coherence with the industrial programme agreement. An under-resourced institute, or one that opens late, will not deliver the skills expected. The restructuring of pharmaceutical training is under way; its impact will depend on aligning construction, funding and skills development, and on the institutional coordination that supports them.